Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Aug;84(15):7662-7.
doi: 10.1128/JVI.02444-09. Epub 2010 May 19.

Cross-reactive neutralizing antibodies directed against pandemic H1N1 2009 virus are protective in a highly sensitive DBA/2 mouse influenza model

Affiliations

Cross-reactive neutralizing antibodies directed against pandemic H1N1 2009 virus are protective in a highly sensitive DBA/2 mouse influenza model

Adrianus C M Boon et al. J Virol. 2010 Aug.

Abstract

Our ability to rapidly respond to an emerging influenza pandemic is hampered somewhat by the lack of a susceptible small-animal model. To develop a more sensitive model, we pathotyped 18 low-pathogenic non-mouse-adapted influenza A viruses of human and avian origin in DBA/2 and C57BL/6 mice. The majority of the isolates (13/18) induced severe morbidity and mortality in DBA/2 mice upon intranasal challenge with 1 million infectious doses. Also, at a 100-fold-lower dose, more than 50% of the viruses induced severe weight loss, and mice succumbed to the infection. In contrast, only two virus strains were pathogenic for C57BL/6 mice upon high-dose inoculation. Therefore, DBA/2 mice are a suitable model to validate influenza A virus vaccines and antiviral therapies without the need for extensive viral adaptation. Correspondingly, we used the DBA/2 model to assess the level of protection afforded by preexisting pandemic H1N1 2009 virus (H1N1pdm) cross-reactive human antibodies detected by a hemagglutination inhibition assay. Passive transfer of these antibodies prior to infection protected mice from H1N1pdm-induced pathogenicity, demonstrating the effectiveness of these cross-reactive neutralizing antibodies in vivo.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Virus titer in lungs of C57BL/6 (•) and DBA/2 (▿) mice at 2 and 7 days postinoculation with 104 EID50 of A/shorebird/Delaware/22/2006 (H7N3), A/blue winged-teal/Alberta/271/2007 (H10N5), and A/California/4/2009 (H1N1pdm). *, P < 0.01. Infectious titer values on the y axis represent EID50/ml for H7N3 and H10N5 viruses and TCID50/ml for H1N1pdm.
FIG. 2.
FIG. 2.
Human cross-reactive 2009 pandemic H1N1-neutralizing antibodies are functional in vivo. Human serum pools with (H1 pos) or without (H1 neg) a detectable cross-reactive 2009 pandemic H1N1 (A/California/4/2009)-neutralizing antibody titer were injected intraperitoneally 24 h prior to intranasal lethal challenge. Control mice were injected with PBS or convalescent-phase serum obtained from 2009 pandemic H1N1 virus-infected ferrets. Survival was monitored for 21 days, and weight loss was monitored for 16 days. Data shown in panel A are the cumulative results of two experiments, and those in panel B represent the average weight loss of one indicative experiment. (A) ***, P < 0.001 compared to results for other groups; **, P < 0.01 compared to results for PBS control group and P < 0.05 compared to results for H1-negative group; *, P < 0.01 compared to results for PBS control group. (B) *, P < 0.01 compared to results for other groups..

References

    1. Boon, A. C., J. Debeauchamp, A. Hollmann, J. Luke, M. Kotb, S. Rowe, D. Finkelstein, G. Neale, L. Lu, R. W. Williams, and R. J. Webby. 2009. Host genetic variation affects resistance to infection with a highly pathogenic H5N1 influenza A virus in mice. J. Virol. 83:10417-10426. - PMC - PubMed
    1. Centers for Disease Control and Prevention. 2009. Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb. Mortal. Wkly. Rep. 58:521-524. - PubMed
    1. Chen, Z., S. Kadowaki, Y. Hagiwara, T. Yoshikawa, K. Matsuo, T. Kurata, and S. Tamura. 2000. Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine 18:3214-3222. - PubMed
    1. Dawood, F. S., S. Jain, L. Finelli, M. W. Shaw, S. Lindstrom, R. J. Garten, L. V. Gubareva, X. Xu, C. B. Bridges, and T. M. Uyeki. 2009. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 360:2605-2615. - PubMed
    1. de Jong, M. D., C. P. Simmons, T. T. Thanh, V. M. Hien, G. J. Smith, T. N. Chau, D. M. Hoang, N. V. Chau, T. H. Khanh, V. C. Dong, P. T. Qui, B. V. Cam, d. Q. Ha, Y. Guan, J. S. Peiris, N. T. Chinh, T. T. Hien, and J. Farrar. 2006. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med. 12:1203-1207. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources